OMCLOmnicell, Inc.

$35.81+14% 1Y

$35.81

$29.4652 weeks$51.39

Is the price fair?

Fair

The yardsticks disagree: cheap against its own 5-year P/E range (10th percentile) but the cash-flow math implies demanding growth. Treat as fair, not cheap.

2 good, 1 to watch

What the price assumes~−0% a yearderived · Jun 30, 2026

Priced for a decline (~−0% a year). The price bakes in little to no growth.

Vs its own P/E rangecheaper than 90% of its own historyderived

Cheap vs its own history: P/E 42.6 vs a 80.9 median over 30 quarters (−47% vs median).

Vs sector (EV/EBIT)310.3×derived · Dec 31, 2025

Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 82% of the market

FCF yieldbetter than 76% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What OMCL's price assumes

Omnicell, Inc. trades at 42.6× earnings against 46.0× for the median Health Information Services name, cheaper than its own group.

42.6

Trailing P/E · Health Information Services median 46.0 · cheaper than the typical name in its group

Price / sales: 1.52
Price / sales · today's price, fiscal year to Dec 31, 2025
Free cash flow yield: 7.9%
Free cash flow yield · Health Information Services median 6.3%
Growth the price implies: −0.49%
Growth the price implies · The price pays for −0.49% free cash flow growth a year for a decade; the business has delivered +0.43% a year over the last three.

Details›

Price / booktoday's price, fiscal year to Dec 31, 2025: 1.46
EV / EBITtoday's price, fiscal year to Dec 31, 2025: 310
EV / salestoday's price, fiscal year to Dec 31, 2025: 1.35
Healthcare median P/E509 names: 26.2
Health Information Services median P/E25 names: 46.0
Free cash flow, trailing twelve months: $143M
Market capitalisation: $1.80B
3-year revenue growth: +0.31%
3-year free cash flow growth: +0.43%

What the market has paid for these earnings: 30 quarters of its own multiple × $0.84 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$50.10
Its own P/E history, median	$67.96
Its own P/E history, upper quartile	$89.72
52-week range	$29.46 – $51.39
Today	$35.81

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

On our screens:Cheap stocks by free cash flow yield

Health Information Services

Ranks #8 of 20 by RyuScore

GoodRx Holdings, Inc.